Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries Life Science Investing
Hope Therapeutics, an NRx Pharmaceuticals Subsidiary , Announces Strategic Partnership with Emobot to Integrate its AI-Powered "Depression Thermometer" Across its Interventional Psychiatry Network Life Science Investing
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm Sublingual Film Pharmaceutical Investing
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy Life Science Investing
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology Annual Meeting Life Science Investing
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity Life Science Investing
Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting Life Science Investing
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology Annual Meeting Life Science Investing
CHAMPION-AF study of the WATCHMAN FLX Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints Life Science Investing
HI-PEITHO trial demonstrates Boston Scientific EKOS Endovascular System is superior to standard of care for treatment of acute pulmonary embolism Life Science Investing
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo Life Science Investing
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy Life Science Investing
